Eli Roth

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

New England Journal of Medicine · 2014 · 596 citations

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial

International Journal of Cardiology · 2014 · First of 9 authors · Corresponding · 222 citations